Opportunities in the peptide and oligonucleotide CDMO market include growing demand for personalized medicine, increased ...

Delray Beach, FL, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Strategic investments in ASO and siRNA platforms, coupled with breakthrough delivery technologies, position oligonucleotide therapeutics as ...

Scientists at St. Jude Children's Research Hospital have found that they can reverse the effects of HNRNPH2-related ...

Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent ...

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

Please provide your email address to receive an email when new articles are posted on . Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential ...

Avidity Biosciences, Inc.'s stock surged ~650% in the past year, driven by positive developments in its Antibody Oligonucleotide Conjugates (AOCs) for muscular disorders. Key catalysts include a ...